Limited stage grade 3 follicular lymphoma patients can experience favorable outcomes with combined modality therapy.
Follicular lymphoma
chemotherapy
radiation
survival
Journal
Leukemia & lymphoma
ISSN: 1029-2403
Titre abrégé: Leuk Lymphoma
Pays: United States
ID NLM: 9007422
Informations de publication
Date de publication:
10 2019
10 2019
Historique:
pubmed:
4
4
2019
medline:
18
8
2020
entrez:
4
4
2019
Statut:
ppublish
Résumé
Controversy exists regarding the optimal management of limited stage grade 3 follicular lymphoma (FL3). We assessed the treatment outcomes of 190 consecutive patients with stage I-II FL. Fifty two patients had FL3 disease, in whom the median age was 55 years. At a median follow-up of 65 months, 5-year progression-free survival (PFS) and overall survival (OS) rates were 76.6% and 87.6%, respectively. Patients receiving systemic therapy followed by radiation therapy (RT) had a significantly better PFS (
Identifiants
pubmed: 30942648
doi: 10.1080/10428194.2019.1597081
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM